OpenAI acquires a biotech start-up to accelerate AI drug development
What's the story
OpenAI has bought Orchestra Bio, a start-up that uses AI to help biotechnology companies. The company was founded four years ago. The companies have not shared the price or other details of the deal. However, Orchestra Bio had raised about $20 million by 2025 from investors including Andreessen Horowitz, Atria, and 8VC. Orchestra's team and technology will become part of OpenAI's Rosalind, an AI model designed to help researchers study the life sciences.
Technology integration
Orchestra Bio's skills in using AI to discover drugs
Orchestra Bio builds AI agents, which are software tools that can carry out tasks, to help biotechnology companies with the process of discovering new drugs.
These tools can do many jobs, such as tracking money and fixing scheduling problems with clinical trials, which are studies that test treatments in people.
Orchestra's technology will be added to OpenAI's Rosalind model and Rosalind Workbench. Workbench is a tool that helps researchers plan experiments and study their results.
Expanding its customer base
Helping the Rosalind model reach more life sciences researchers
OpenAI is buying Orchestra Bio as it continues to find more customers for its Rosalind model.
OpenAI says that major companies such as Moderna and Novo Nordisk are already using the model for life sciences research.
Adding Orchestra's technology and team to Rosalind is expected to make the model more useful for work in biotechnology.